الفهرس Only 14 pages are availabe for public view
 |  | from | 264 |  |  |
| | | from | 264 | | |
Abstract
Central retinal vein occlusion (CRVO) is caused by blood clot in the central retinal vein, which slows or stops blood from leaving the retina. Although at first blood may continue to enter the retina through central retinal artery, the blockage ultimately stops blood circulation. (Bynoe, .et al., 2005)
Branch retinal vein occlusion (BRVO) is more common than CRVO and has more favorable prognosis. The onset is usually sudden with blurred vision and metamorphopsia or relative visual field defect; occasionally BRVO may have no effect on visual function. (Hayreh, .et al., 1994)
The medical treatment of retinal vein occlusion (RVO) is composed of three main stages : identification and therapy of the detectable risk factors , specific treatment and treatment of the complications, specific treatment includes Anticoagulant / antiaggregating agents, corticosteroid, fibrinolytic thrombolytic agents, and hemodilution . Overall, the medical approach to retinal vein occlusion is still unsatisfactory. (Parodi. 2004)
The mainstay of treatment of CRVO was by panretinal photocoagulation to prevent or treat neovascularization. Prophylactic panretinal photocoagulation was used to reduce the incidence of neovascularization and cystoid macular edema but had no effect on visual acuity. (Laatikainen, .et al., 1977)